at resmed (nyse: rmd, asx: rmd) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. our cloud-connected medical devices transform care for people with sleep apnea, copd and other chronic diseases. our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. by enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries.
Company profile
Ticker
RMD
Exchange
Website
CEO
Michael Farrell
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
ResMed Corp. • ResMed (UK) Ltd • ResMed Asia Pacific Ltd • ResMed Beteiligungs GmbH • ResMed Holdings Pty Ltd • ResMed Pty Ltd • ResMed GmbH and Co • ResMed Motor Technologies Inc. • ResMed SAS • ResMed Paris SAS ...
IRS number
980152841
RMD stock data
Latest filings (excl ownership)
10-Q
2024 Q2
Quarterly report
25 Jan 24
8-K
ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2024
24 Jan 24
8-K
Amendments to Articles of Incorporation or Bylaws
20 Nov 23
8-K
ResMed Adopts New Operating Model to Accelerate Long-term Growth
9 Nov 23
10-Q
2024 Q1
Quarterly report
26 Oct 23
8-K
ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2024
26 Oct 23
DEFR14A
Revised proxy
13 Oct 23
ARS
2023 FY
Annual report to shareholders
5 Oct 23
DEFA14A
Additional proxy soliciting materials
5 Oct 23
DEF 14A
Definitive proxy
5 Oct 23
Transcripts
RMD
Earnings call transcript
2024 Q2
24 Jan 24
RMD
Earnings call transcript
2024 Q1
26 Oct 23
RMD
Earnings call transcript
2023 Q4
3 Aug 23
RMD
Earnings call transcript
2023 Q3
27 Apr 23
RMD
Earnings call transcript
2023 Q2
26 Jan 23
RMD
Earnings call transcript
2023 Q1
28 Oct 22
RMD
Earnings call transcript
2022 Q4
12 Aug 22
RMD
Earnings call transcript
2022 Q3
29 Apr 22
RMD
Earnings call transcript
2022 Q2
28 Jan 22
RMD
Earnings call transcript
2022 Q1
29 Oct 21
Latest ownership filings
4
Michael J Rider
6 Mar 24
4
Michael J Rider
4 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
144
Notice of proposed sale of securities
1 Mar 24
4
PETER C FARRELL
23 Feb 24
144
Notice of proposed sale of securities
22 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
144
Notice of proposed sale of securities
6 Feb 24
SC 13G/A
BlackRock Inc.
25 Jan 24
4
Robert Andrew Douglas
3 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 23 | Jun 22 | Jun 21 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 209.10 mm | 209.10 mm | 209.10 mm | 209.10 mm | 209.10 mm | 209.10 mm |
Cash burn (monthly) | 6.26 mm | (no burn) | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 42.90 mm | n/a | n/a | n/a | n/a | n/a |
Cash remaining | 166.20 mm | n/a | n/a | n/a | n/a | n/a |
Runway (months of cash) | 26.5 | n/a | n/a | n/a | n/a | n/a |
Institutional ownership, Q3 2023
58.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 648 |
Opened positions | 71 |
Closed positions | 128 |
Increased positions | 240 |
Reduced positions | 244 |
13F shares | Current |
---|---|
Total value | 12.71 tn |
Total shares | 86.07 mm |
Total puts | 480.30 k |
Total calls | 670.50 k |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 17.57 mm | $2.60 tn |
BLK Blackrock | 12.10 mm | $1.79 tn |
STT State Street | 6.16 mm | $911.39 bn |
FMR | 3.81 mm | $563.59 bn |
Geode Capital Management | 3.39 mm | $499.99 bn |
MS Morgan Stanley | 2.33 mm | $344.48 bn |
IVZ Invesco | 2.01 mm | $296.79 bn |
Citadel Advisors | 1.72 mm | $254.27 bn |
NTRS Northern Trust | 1.49 mm | $220.51 bn |
BK Bank Of New York Mellon | 1.14 mm | $168.42 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 Mar 24 | Michael J Rider | ResMed Common Stock | Sell | Dispose S | No | Yes | 180 | 81 | 14.58 k | 6,607 |
1 Mar 24 | Michael J Rider | ResMed Common Stock | Sell | Dispose S | No | Yes | 173.25 | 200 | 34.65 k | 6,688 |
27 Nov 23 | Sandercock Brett | ResMed Common Stock | Sell | Dispose S | No | No | 152.6201 | 3,000 | 457.86 k | 92,962 |
22 Nov 23 | Michael J Rider | ResMed Common Stock | Gift | Dispose G | No | No | 0 | 72 | 0.00 | 6,888 |
News
Here's How Much You Would Have Made Owning ResMed Stock In The Last 15 Years
15 Apr 24
Jim Cramer Isn't Going With This Tech Company: 'It's Complicated. I'm A Nvidia Guy'
8 Apr 24
Needham Maintains Buy on ResMed, Raises Price Target to $224
1 Apr 24
$1000 Invested In ResMed 10 Years Ago Would Be Worth This Much Today
28 Mar 24
Expert Outlook: ResMed Through The Eyes Of 9 Analysts
27 Mar 24
Press releases
ResMed to Report Third Quarter Fiscal 2024 Earnings on April 25, 2024
4 Apr 24
ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis
15 Mar 24
ResMed's New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea
12 Feb 24
MatrixCare Earns Three 2024 Best in KLAS Awards
7 Feb 24